These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2181151

  • 1. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
    Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU.
    J Natl Cancer Inst; 1990 Apr 18; 82(8):667-72. PubMed ID: 2181151
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 18; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ, Iscoe N, Tannock IF.
    J Urol; 1993 Oct 18; 150(4):1131-4. PubMed ID: 8371371
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN, de Mulder PH, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR.
    Ann Oncol; 1993 May 18; 4(5):403-7. PubMed ID: 8353075
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    J Clin Oncol; 2001 May 15; 19(10):2638-46. PubMed ID: 11352955
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF.
    J Clin Oncol; 2000 Sep 15; 18(17):3068-77. PubMed ID: 11001674
    [Abstract] [Full Text] [Related]

  • 10. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 15; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 11. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA, Scher HI.
    Cancer; 1992 Dec 01; 70(11):2699-702. PubMed ID: 1384952
    [Abstract] [Full Text] [Related]

  • 12. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE.
    N Engl J Med; 1988 Sep 08; 319(10):593-8. PubMed ID: 3045544
    [Abstract] [Full Text] [Related]

  • 13. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
    Long HJ, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA.
    Am J Clin Oncol; 2002 Dec 08; 25(6):547-51. PubMed ID: 12477995
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
    Rifkin RM, Hersh EM, Salmon SE.
    Behring Inst Mitt; 1988 Aug 08; (83):125-33. PubMed ID: 3071327
    [Abstract] [Full Text] [Related]

  • 15. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.
    Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D.
    Blood; 1989 Jan 08; 73(1):31-7. PubMed ID: 2642714
    [Abstract] [Full Text] [Related]

  • 16. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M, Kadena H, Ueda M, Usui T.
    Cancer Chemother Pharmacol; 1994 Jan 08; 35 Suppl():S1-4. PubMed ID: 7527732
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
    Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andreesen R, Fiedler W.
    Cancer; 1990 Aug 01; 66(3):423-30. PubMed ID: 2194641
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 19. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T, Obara T, Saito M, Kumazawa T, Yuasa T, Matuura S, Tsuchiya N, Satoh S, Habuchi T.
    Hinyokika Kiyo; 2007 Sep 15; 53(9):613-8. PubMed ID: 17933135
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, Bonadonna G.
    J Clin Oncol; 1990 May 15; 8(5):768-78. PubMed ID: 2185337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.